Latest Non Dilutive Funding News

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

EV Resources has partnered with U.S.-based MineMaker LLC to accelerate its antimony projects in Mexico and Nevada, aiming to become a key supplier to North America’s critical minerals market.

Premier1 Lithium has kicked off a significant 3,700-metre drilling program at its Mt Kersey Prospect within the Yalgoo Gold Project, aiming to unlock the potential of a large gold-in-soil anomaly and preserved hydrothermal system in Western Australia.

Stavely Minerals has locked in a $500,000 unsecured director loan facility to fund its 2026 Scoping Study targeting copper, gold, and silver production. This non-dilutive funding move underscores confidence from within the board as the company advances key projects.

Litchfield Minerals has secured a coveted spot in BHP’s 2026 Xplor accelerator, gaining $500,000 in non-dilutive funding and expert support to fast-track its Oonagalabi Project exploration.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

Altamin Limited progresses its Lazio geothermal lithium and SOP project with key technical studies and grant funding, while advancing a strategic sale process for its Gorno polymetallic project. The company bolsters its balance sheet through a successful entitlement offer raising A$5.39 million.

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.